Immunotherapy plus chemotherapy vs. chemotherapy alone for stage 3 colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (CAPEOX) is more effective than chemotherapy alone for people with a specific type of colon cancer (MMRp/MSS) that has not spread. It is given before surgery to shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer that has not been treated yet
- Your cancer is T4N0 or stage 3 and can be surgically removed
- Your tumor is MMR-proficient or microsatellite stable (common types of colon cancer)
- You are willing to provide a fresh tumor sample via colonoscopy
- You have good performance status (able to do daily activities) and normal organ function
- You have not had prior treatment for colon cancer (like chemotherapy or immunotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
Hear when a new Neoplasms, Colon trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.